Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA

Science

Volumn 279, Issue 5359, 1998, Pages 2103-2106

  Ogg, Graham S ^a   Jin, Xia ^b   Bonhoeffer, Sebastian ^b,c   Dunbar, P Rod ^a   Nowak, Martin A ^c   Monard, Simon ^b   Segal, Jeremy P ^b   Cao, Yunzhen ^b   Rowland Jones, Sarah L ^a   Cerundolo, Vincenzo ^a   Hurley, Arlene ^b   Markowitz, Martin ^b   Ho, David D ^b   Nixon, Douglas F ^b   McMichael, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COLORING AGENTS; CYTOPATHOGENIC EFFECT, VIRAL; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; HIV INFECTIONS; HIV-1; HLA-A ANTIGENS; HUMANS; LYMPHOCYTE COUNT; OLIGOPEPTIDES; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD; VIREMIA;

EID: 7144227284     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.279.5359.2103     Document Type: Article

References (44)

1. J. W. Mellors et al., Ann. Intern. Med. 122, 573 (1995); J. W. Mellors et al., Science 272, 1167 (1996); J. W. Mellors et al., Ann. Intern. Med. 126, 946 (1997); T. R. O'Brien et al., J. Am. Med. Assoc. 276, 105 (1996).
2. J. W. Mellors et al., Ann. Intern. Med. 122, 573 (1995); J. W. Mellors et al., Science 272, 1167 (1996); J. W. Mellors et al., Ann. Intern. Med. 126, 946 (1997); T. R. O'Brien et al., J. Am. Med. Assoc. 276, 105 (1996).
3. J. W. Mellors et al., Ann. Intern. Med. 122, 573 (1995); J. W. Mellors et al., Science 272, 1167 (1996); J. W. Mellors et al., Ann. Intern. Med. 126, 946 (1997); T. R. O'Brien et al., J. Am. Med. Assoc. 276, 105 (1996).
4. J. W. Mellors et al., Ann. Intern. Med. 122, 573 (1995); J. W. Mellors et al., Science 272, 1167 (1996); J. W. Mellors et al., Ann. Intern. Med. 126, 946 (1997); T. R. O'Brien et al., J. Am. Med. Assoc. 276, 105 (1996).
5. R. A. Koup et al. J. Virol. 68, 4650 (1994).
6. P. Borrow et al., ibid., p. 6103.
7. R. E. Phillips et al., Nature 354, 453 (1991).
8. S. Koenig et al., Nature Med. 1, 330 (1995); P. Borrow et al., ibid. 3, 205 (1997); D. A. Price et al., Proc. Natl. Acad. Sci. U.S.A. 94, 1890 (1997); P. J. R. Goulder et al., Nature Med. 3, 212 (1997).
9. S. Koenig et al., Nature Med. 1, 330 (1995); P. Borrow et al., ibid. 3, 205 (1997); D. A. Price et al., Proc. Natl. Acad. Sci. U.S.A. 94, 1890 (1997); P. J. R. Goulder et al., Nature Med. 3, 212 (1997).
10. S. Koenig et al., Nature Med. 1, 330 (1995); P. Borrow et al., ibid. 3, 205 (1997); D. A. Price et al., Proc. Natl. Acad. Sci. U.S.A. 94, 1890 (1997); P. J. R. Goulder et al., Nature Med. 3, 212 (1997).
11. S. Koenig et al., Nature Med. 1, 330 (1995); P. Borrow et al., ibid. 3, 205 (1997); D. A. Price et al., Proc. Natl. Acad. Sci. U.S.A. 94, 1890 (1997); P. J. R. Goulder et al., Nature Med. 3, 212 (1997).
12. C. M. Walker et al., Science 234, 1563 (1986); F. Cocchi et al., ibid. 270, 1811 (1995).
13. C. M. Walker et al., Science 234, 1563 (1986); F. Cocchi et al., ibid. 270, 1811 (1995).
14. P. Klenerman et al., Proc. Natl. Acad. Sci. U.S.A. 93, 15323 (1996).
15. S. Bonhoeffer et al., ibid. 94, 6971 (1997); M. A. Nowak and C. R. M. Bangham, Science 272, 74 (1996).
16. S. Bonhoeffer et al., ibid. 94, 6971 (1997); M. A. Nowak and C. R. M. Bangham, Science 272, 74 (1996).
17. M. D. Grant et al., AIDS 6, 1085 (1992).
18. C. R. Rinaldo et al., AIDS Res. Hum. Retroviruses 11, 481 (1995).
19. T. C. Greenough et al., J. Infect. Dis. 176, 118 (1997).
20. Y. Cao et al., N. Engl. J. Med. 332, 201 (1995); T. Harrer et al., J. Immunol. 156, 2616 (1996); C. Rinaldo et al., J. Virol. 69, 5838 (1995); M. R. Klein et al., J. Exp. Med. 181, 1365 (1995); K. Ariyoshi et al., AIDS 9, 555 (1995).
21. Y. Cao et al., N. Engl. J. Med. 332, 201 (1995); T. Harrer et al., J. Immunol. 156, 2616 (1996); C. Rinaldo et al., J. Virol. 69, 5838 (1995); M. R. Klein et al., J. Exp. Med. 181, 1365 (1995); K. Ariyoshi et al., AIDS 9, 555 (1995).
22. Y. Cao et al., N. Engl. J. Med. 332, 201 (1995); T. Harrer et al., J. Immunol. 156, 2616 (1996); C. Rinaldo et al., J. Virol. 69, 5838 (1995); M. R. Klein et al., J. Exp. Med. 181, 1365 (1995); K. Ariyoshi et al., AIDS 9, 555 (1995).
23. Y. Cao et al., N. Engl. J. Med. 332, 201 (1995); T. Harrer et al., J. Immunol. 156, 2616 (1996); C. Rinaldo et al., J. Virol. 69, 5838 (1995); M. R. Klein et al., J. Exp. Med. 181, 1365 (1995); K. Ariyoshi et al., AIDS 9, 555 (1995).
24. Y. Cao et al., N. Engl. J. Med. 332, 201 (1995); T. Harrer et al., J. Immunol. 156, 2616 (1996); C. Rinaldo et al., J. Virol. 69, 5838 (1995); M. R. Klein et al., J. Exp. Med. 181, 1365 (1995); K. Ariyoshi et al., AIDS 9, 555 (1995).
25. L. Musey et al., N. Engl. J. Med. 337, 1267 (1997).
26. F. M. Gotch et al., Int. Immunol. 2, 707 (1990); P. A. H. Moss et al., Proc. Natl. Acad. Sci. U.S.A. 92, 5773 (1995).
27. F. M. Gotch et al., Int. Immunol. 2, 707 (1990); P. A. H. Moss et al., Proc. Natl. Acad. Sci. U.S.A. 92, 5773 (1995).
28. J. D. Altman et al., Science 274, 94 (1996); G. S. Ogg et al., in preparation; P. R. Dunbar et al., in preparation.
29. J. D. Altman et al., Science 274, 94 (1996); G. S. Ogg et al., in preparation; P. R. Dunbar et al., in preparation.
30. J. D. Altman et al., Science 274, 94 (1996); G. S. Ogg et al., in preparation; P. R. Dunbar et al., in preparation.
31. 2+ (Sigma). Streptavidin-phycoerythrin conjugate (Leinco) was added in a 1:4 molar ratio, and the tetrameric product was concentrated to 1 mg/ml.
32. H. Shiga et al., AIDS 10, 1075 (1996).
33. K. C. Parker et al., J. Immunol. 149, 3580 (1992).
34. T. J. Tsomides et al., Proc. Natl. Acad. Sci. U.S.A. 88, 11276 (1991).
35. Abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
36. 5 PBMCs was added to each well after counting in the presence of trypan blue. The plates were incubated at 37°C for 4 hours before harvesting 20 μl of supernatant. Percentage lysis was estimated as [(experimental counts - media control) × 100]/(detergent counts - media control). Lysis of non-peptide controls was subtracted to give peptide-specific lysis. Media controls were between 10 to 15% of detergent controls.
37. 6 irradiated PBMCs from at least three donors, together with phytohemagglutinin (5 μg/ ml, Wellcome) in RPMI 1640 (Gibco) supplemented with glutamine, penicillin, streptomycin, and 5% human serum. After 4 days, Lymphocult-T (Biotest) was added to a final concentration of 10%. After 3 weeks the cultures were expanded into 24-well plates.
38. P. J. R. Goulder et al., J. Exp Med. 185, 1423 (1997).
39. A. Carmichael et al., ibid. 177, 249 (1993).
40. D. D. Ho et al., Nature 373, 123 (1995); X. Wei et al., ibid., p. 117.
41. D. D. Ho et al., Nature 373, 123 (1995); X. Wei et al., ibid., p. 117.
42. B. Autran et al., Science 277, 112 (1997).
43. N. Steven et al., J. Exp. Med. 185, 1605 (1997).
44. The assistance of the nursing staff at Rockefeller Hospital and of J. Jin and J. Song in processing PBMC samples is gratefully acknowledged. Supported by grants from NIH (U01AI41534) and General Clinical Research Center (GCRC) (MO1-RR00102). G.S.O., P.R.D., V.C., S.L.R.-J, and A.J.M. are funded by the Medical Research Council (UK). S.B. and N.A.M. are supported by the Wellcome Trust.